Negligent misrepresentation: Lawsuits accuse Novo Nordisk of overstating the potential benefits of Ozempic while minimizing or obscuring some of its risks
cite Government programs historically limited coverage for weight-loss indications, but policy shifts are underway that may broaden access and lower costs for Medicare and Medicaid in coming years
Data for these treatments are limited, and they are elective not medically necessary
Weight loss can be challenging for many people, even those who maintain consistent diet and exercise routines
There have been a number of systematic reviews/meta-analyses of controlled trials of selenium treatment in patients with AITD/HT ( Reference Schomburg 70 , Reference Wichman, Bonnema and Hegedus 88 Reference Fan, Xu and Zhang 90 )
For clinicians seeking broader guidance, the American Diabetes Association Standards of Care provide valuable context for integrating GLP-1 receptor agonists into comprehensive cardiometabolic management